Question 1

Am I eligible for this trial based on my tumor's genetic profile?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype clinical trial (NCT02658279). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of pembrolizumab?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype clinical trial (NCT02658279). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype clinical trial (NCT02658279). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment schedule look like?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype clinical trial (NCT02658279). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any additional tests or procedures I need to undergo?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype clinical trial (NCT02658279). Contact the study team or your healthcare provider for specific answers.

Question 6

What support is available if I experience side effects?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype clinical trial (NCT02658279). Contact the study team or your healthcare provider for specific answers.

What this study is about